NASDAQ:IOVA
Iovance Biotherapeutics, Inc. Stock News
$10.01
-0.250 (-2.44%)
At Close: May 24, 2024
Iovance (IOVA) to Start Clinical Studies for TIL Therapy
03:57pm, Wednesday, 16'th Mar 2022 Zacks Investment Research
Iovance (IOVA) gets FDA nod to start clinical study for IOV-4001, which utilizes the technology licensed from Cellectis. A clinical study in melanoma or NSCLC indication is expected to begin in 2022.
Iovance (IOVA) to Start Clinical Studies for TIL Therapy
01:32pm, Wednesday, 16'th Mar 2022
Iovance (IOVA) gets FDA nod to start clinical study for IOV-4001, which utilizes the technology licensed from Cellectis. A clinical study in melanoma or NSCLC indication is expected to begin in 2022.
Iovance Receives FDA Allowance For IOV-4001 Study In Two Advanced Cancers
01:21pm, Wednesday, 16'th Mar 2022 Benzinga
The FDA has signed off Iovance Biotherapeutics Inc''s (NASDAQ: IOVA ) Investigational New Drug Application (IND) first genetically modified TIL therapy, IOV-4001, for unresectable or metastatic melanoma and stage III or IV non-small-cell lung cancer (NSCLC). IOV-4001 leverages the gene-editing TALEN technology licensed from Cellectis SA (NASDAQ: Full story available on Benzinga.com
The Daily Biotech Pulse: Pfizer-BioNTech Apply For Authorization Of 3rd Booster Shot, Sanofi-Seagen Strike Cancer Therapy Pact, Iovance Gets Nod For Cancer Study
12:02pm, Wednesday, 16'th Mar 2022 Benzinga
Here''s a roundup of top developments in the biotech space over the last 24 hours. Stocks In Focus Pfizer, BioNTech File For Authorization Of Second Booster Dose Of COVID-19 Vaccine Pfizer, Inc. (NYSE: PFE ) and BioNTech SE (NASDAQ: BNTX ) said they have submitted an application to the U.S. Food and Drug Administration for the emergency use authorization of an additional booster dose for adults, 65 years of age and older, who have received an initial booster of any of the authorized or approved COVID-19 vaccines. Earlier this month, a CDC study found that the duo''s COVID-19 vaccine becomes less effective after four months following vaccination. Pfizer shares were up 0.73% at $52.59 in premarket trading and BioNTech shares were advancing 3.58% to $150.23. Iovance Gets FDA Approval to Commence Study Of TIL Therapy to Treat Lung Cancer Iovance Biotherapeutics, Inc. (NASDAQ: IOVA ) said the FDA has allowed an investigational new drug application to proceed with its first genetically modified tumor-infiltrating lymphocyte (TIL) therapy, IOV-4001, for the treatment of unresectable or metastatic melanoma and stage 3 or 4 non-small cell lung cancer.
Iovance Biotherapeutics to Present at Upcoming Conferences
11:01am, Wednesday, 16'th Mar 2022 GlobeNewswire Inc.
SAN CARLOS, Calif., March 16, 2022 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ: IOVA), a late-stage biotechnology company developing novel T cell-based cancer immunotherapies, today an
Iovance Biotherapeutics to Present at Upcoming Conferences
07:01am, Wednesday, 16'th Mar 2022
SAN CARLOS, Calif., March 16, 2022 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ: IOVA), a late-stage biotechnology company developing novel T cell-based cancer immunotherapies, today anno
LAND, INMD and DADA among after hour movers
09:33pm, Tuesday, 15'th Mar 2022 Seeking Alpha
Gainers: Iovance Biotherapeutics, Inc. IOVA +12%.
Iovance Biotherapeutics Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4)
09:15pm, Tuesday, 15'th Mar 2022 GlobeNewswire Inc.
SAN CARLOS, Calif., March 15, 2022 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ: IOVA), a late-stage biotechnology company developing novel T cell-based cancer immunotherapies, today an
Clinical Study Expected to Begin in 2022 to Investigate the Safety and Efficacy of IOV-4001 to Deliver TIL and PD-1 Inhibition within a Single Cancer Therapy
Clinical Study Expected to Begin in 2022 to Investigate the Safety and Efficacy of IOV-4001 to Deliver TIL and PD-1 Inhibition within a Single Cancer Therapy First Genetically Modified Iovance TIL Therapy Leverages TALEN® technology Licensed from Cellectis to Inactivate PD-1 Expression SAN CARLOS, Calif., March 15, 2022 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ: IOVA ), a late-stage biotechnology company developing novel T cell-based cancer immunotherapies, today announced that the U.S. Food and Drug Administration (FDA) has allowed an Investigational New Drug Application (IND) to proceed for its first genetically modified TIL therapy, IOV-4001, for the treatment of unresectable or metastatic melanoma and stage III or IV NSCLC. IOV-4001 leverages the gene editing TALEN® technology licensed from Cellectis (NASDAQ: CLLS ), a clinical-stage biotechnology company using its pioneering gene-editing platform to develop potentially life-saving cell and gene therapies, to inactivate the gene coding for the PD-1 protein.
Iovance Biotherapeutics to Present at American Association for Cancer Research (AACR) 2022 Annual Meeting
09:31pm, Tuesday, 08'th Mar 2022 GlobeNewswire Inc.
SAN CARLOS, Calif., March 08, 2022 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ: IOVA), a late-stage biotechnology company developing novel T cell-based cancer immunotherapies, today an
Iovance Biotherapeutics to Present at American Association for Cancer Research (AACR) 2022 Annual Meeting
04:31pm, Tuesday, 08'th Mar 2022
SAN CARLOS, Calif., March 08, 2022 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ: IOVA), a late-stage biotechnology company developing novel T cell-based cancer immunotherapies, today anno
Iovance (IOVA) Announces Wider-Than-Anticipated Q4 Loss
02:59pm, Friday, 25'th Feb 2022 Zacks Investment Research
Iovance Biotherapeutics' (IOVA) fourth-quarter loss is wider than expected. The company is on track to file regulatory submission for lifileucel in melanoma by first-half 2022.
Iovance (IOVA) Announces Wider-Than-Anticipated Q4 Loss
11:31am, Friday, 25'th Feb 2022
Iovance Biotherapeutics' (IOVA) fourth-quarter loss is wider than expected. The company is on track to file regulatory submission for lifileucel in melanoma by first-half 2022.
Iovance Biotherapeutics' (IOVA) CEO Fred Vogt on Q4 2021 Results - Earnings Call Transcript
08:38pm, Thursday, 24'th Feb 2022
Iovance Biotherapeutics' (IOVA) CEO Fred Vogt on Q4 2021 Results - Earnings Call Transcript